医学
伊立替康
贝伐单抗
中性粒细胞减少症
内科学
贫血
养生
不利影响
临床研究阶段
肿瘤科
恶心
发热性中性粒细胞减少症
结直肠癌
腹泻
白细胞减少症
外科
胃肠病学
化疗方案
临床终点
化疗
挽救疗法
耐受性
存活率
无进展生存期
临床试验
作者
Wenwei Yang,Lei Zhang,Ping Liang,Zhaoye Qian,Donghui Wang,Wen Zhang,Baoqi Li,Chengxu Cui,Xiaomin Zhong,Guifu Wu,Yongkun Sun
标识
DOI:10.1038/s41392-026-02634-3
摘要
Patients diagnosed with metastatic colorectal cancer (mCRC) face a constrained therapeutic landscape following the failure of initial treatment. This multicenter, single-arm, phase II trial (NCT06202001) aimed to assess the efficacy and safety of a novel second-line regimen comprising trifluridine/tipiracil (TAS-102), irinotecan, and bevacizumab. Patients with mCRC resistant to prior fluoropyrimidine and oxaliplatin-based chemotherapy were enrolled. Based on a preceding phase I trial, patients received biweekly cycles of oral TAS-102 (30 mg/m² twice daily, days 1-5), intravenous irinotecan (150 mg/m²), and intravenous bevacizumab (5 mg/kg). The primary outcome measure was the objective response rate (ORR). From October 2023 to August 2024, 60 patients were enrolled. As of December 2024, the ORR was 18.3% (2 complete and 9 partial responses), and the disease control rate (DCR) was 83.3%. The median progression-free survival (PFS) was 6.6 months (95% CI, 4.39-8.81), and the median overall survival (OS) was 17.3 months (95% CI, 13.55-21.05). Subgroup analyses indicated that prior resection of the primary tumor was associated with significantly longer median OS (21.9 vs. 16.2 months; p = 0.048) and PFS (8.9 vs. 5.2 months; p = 0.004). The most frequently reported treatment-related adverse events (TRAEs) were nausea (100%), neutropenia (86.7%), and anemia (83.3%). The predominant grade 3/4 TRAEs included neutropenia (48.3%), febrile neutropenia (8.3%), and diarrhea (6.7%). In conclusion, the combination of irinotecan, TAS-102, and bevacizumab shows encouraging efficacy and a manageable safety profile as a second-line therapy for mCRC, meriting further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI